Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 6/20 | 0.50 |
| ▸ | CES2 | O00748 | 4/20 | 0.50 |
| ▸ | CES1 | P23141 | 4/20 | 0.50 |
| ▸ | PPARG | P37231 | 4/20 | 0.43 |
| ▸ | PPARD | Q03181 | 4/20 | 0.43 |
| ▸ | PPARA | Q07869 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6135534 | 1.00 | FABP3 (0.50) | FABP3CES2CES1PPARGPPARD | |
| SCHEMBL19210221 | 1.00 | FABP3 (0.50) | FABP3CES2CES1PPARGPPARD | |
| Zinc Ion SCHEMBL9731009 | 0.96 | FABP3 (0.50) | FABP3CES2CES1PPARGPPARD | |
| SCHEMBL9679131 | 0.96 | FABP3 (0.50) | FABP3CES2CES1PPARGPPARD | |
| SCHEMBL10731314 | 0.96 | FABP3 (0.50) | FABP3CES2CES1PPARGPPARD | |
| Zinc Ion SCHEMBL10726528 | 0.96 | FABP3 (0.50) | FABP3CES2CES1PPARGPPARD | |
| Zinc Ion SCHEMBL9704026 | 0.96 | FABP3 (0.50) | FABP3CES2CES1PPARGPPARD | |
| SCHEMBL9679116 | 0.96 | FABP3 (0.50) | FABP3CES2CES1PPARGPPARD | |
| SCHEMBL10732351 | 0.96 | FABP3 (0.50) | FABP3CES2CES1PPARGPPARD | |
| SCHEMBL11860350 | 0.96 | FABP3 (0.50) | FABP3CES2CES1PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116509844-B | Pharmaceutical composition of dipeptidyl peptidase 4 inhibitor and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2024-06-04 | — | — | CN | claimed |
| US-20240115575-A1 | PHARMACEUTICAL COMPOSITION OF MULTI-TARGET PROTEIN KINASE INHIBITORS, AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2024-04-11 | — | — | US | claimed |
| CN-117427143-A | Pharmaceutical composition containing peptidomimetic compounds and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2024-01-23 | — | — | CN | claimed |
| EP-4272741-A1 | PHARMACEUTICAL COMPOSITION OF MULTI-TARGET PROTEIN KINASE INHIBITORS, AND USE THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2023-11-08 | — | — | EP | claimed |
| WO-2023186031-A1 | PHARMACEUTICAL COMPOSITION OF MULTI-TARGET PROTEIN KINASE INHIBITOR, USE THEREOF, AND METHOD FOR PREPARING SAME | 石药集团中奇制药技术（石家庄）有限公司 | 2023-10-05 | — | — | WO | claimed |
| CN-114699378-B | Sitagliptin phosphate pharmaceutical preparation and preparation method thereof | 北京福元医药股份有限公司 | 2023-09-26 | — | — | CN | claimed |
| CN-114641277-B | Pharmaceutical composition of dipeptidyl peptidase 4 inhibitor and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2023-06-13 | — | — | CN | claimed |
| CN-114699378-A | Sitagliptin phosphate pharmaceutical preparation and preparation method thereof | 北京福元医药股份有限公司 | 2022-07-05 | — | — | CN | claimed |
| WO-2021136507-A1 | PHARMACEUTICAL COMPOSITION OF DIPEPTIDYL PEPTIDASE-4 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2021-07-08 | — | — | WO | claimed |
| US-9717707-B2 | Pharmaceutical statin composition | HEXAL AG (DE) | 2017-08-01 | — | — | US | claimed |
| US-20170065531-A9 | ALCOHOL-RESISTANT ORAL PHARMACEUTICAL FORM | ETHYPHARM SA (FR) | 2017-03-09 | — | — | US | claimed |
| EP-2787987-B1 | NEW PHARMACEUTICAL STATIN COMPOSITIONS | HEXAL AG (DE) | 2016-06-01 | — | — | EP | claimed |
| US-20150250737-A1 | ALCOHOL-RESISTANT ORAL PHARMACEUTICAL FORM | ETHYPHARM SA (FR) | 2015-09-10 | — | — | US | claimed |
| US-20140328936-A1 | NOVEL PHARMACEUTICAL STATIN COMPOSITION | HEXAL AG (DE) | 2014-11-06 | — | — | US | claimed |
| US-20130059010-A1 | ALCOHOL-RESISTANT ORAL PHARMACEUTICAL FORM | ETHYPHARM (FR) | 2013-03-07 | — | — | US | claimed |
| EP-2965752-B1 | PHARMACEUTICAL FORMULATION COMPRISING EZETIMIBE | ASSIA CHEM IND LTD (IL) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025078588-A1 | METHOD AND SYSTEM FOR PREPARING AGGLOMERATED EXCIPIENT GRANULES | DFE PHARMA GMBH & CO. KG (DE) | 2025-04-17 | — | — | WO | disclosed |
| US-4920144-A | Derivatives of bicyclic amino acids, agents containing them and their use as hypotensives | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-04-24 | — | — | US | disclosed |
| US-4855286-A | HYPOTENSIVE AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-08 | — | — | US | disclosed |
| US-4111886-A | PLASTICS COMPOSITIONS WITH HIGHER ALCOHOL ESTERS AS LUBRICANTS AND RELEASE AGENTS | HENKEL INC. (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115575-A1 | PHARMACEUTICAL COMPOSITION OF MULTI-TARGET PROTEIN KINASE INHIBITORS, AND USE THEREOF | DMPK, PRKCB, PRKCA | FABP3 2940/4885CES2 4577/4885CES1 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.